Your session is about to expire
← Back to Search
BLd Combination Therapy for Multiple Myeloma
Study Summary
This trial is testing a new combination therapy for multiple myeloma. The goal is to find the highest dose of the combination that can be given safely, and to see how well it works in newly diagnosed patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 393 Patients • NCT00004228Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have signs of bleeding from your mouth or inside your body, or your platelets are not working properly.I do not have any serious infections or health conditions.My diabetes is not well-controlled.I have been diagnosed with POEMS syndrome.Your absolute neutrophil count is less than 1000 cells per cubic millimeter.Your liver enzymes (AST or ALT) are more than double the normal level.I am currently taking corticosteroids.My kidney function is reduced with a creatinine level over 2.5 mg/dL.I haven't had a heart attack or severe heart issues in the last 6 months.I have had skin, cervical, breast, or prostate cancer but it was treated successfully.Your hemoglobin level is less than 8.0 grams per deciliter.I have an active hepatitis B or C infection.I have not received any systemic therapy for my multiple myeloma.You are allergic to acyclovir or similar antiviral drugs.You have to have a negative pregnancy test from a blood or urine sample.I have moderate to severe numbness, tingling, or pain in my hands or feet.I am 18 years old or older.You cannot tolerate steroid medications.I have been diagnosed with multiple myeloma.I can care for myself but may not be able to do active work.I have been diagnosed with HIV.
- Group 1: lenalidomide, dexamethasone, bortezomib combination
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide any details on past experiments involving dexamethasone?
"At the present moment, there are 733 clinical trials being conducted to evaluate dexamethasone. Of these studies, 168 are in their final stage of evaluation (Phase 3). While most of the experiments occur at a single location in Joliet, Illinois; 26098 other sites around the world are running research into this medication."
Is this research endeavor currently open to new participants?
"As indicated by information posted on clinicaltrials.gov, this research trial is no longer recruiting participants. The study was initially announced in September of 2006 and the last update made to its page happened on March 29th 2022. Despite this particular project not being actively seeking new candidates right now, there are 1540 other trials which do require enrolment at present moment."
What indications have been found to respond best to dexamethasone therapy?
"Dexamethasone can be used to treat a wide variety of afflictions, such as ophthalmia nervosa and sympathetic edema. This medication has also been approved for use in cases involving branch retinal vein occlusion and macular edema that have not responded to two prior chemotherapy regimens."
What is the aggregate participation figure of this medical experiment?
"This clinical trial is no longer open for recruitment. Originally posted on September 1st 2006, the listing was last updated on March 29th 2022. However, there are currently 807 trials related to multiple myeloma and 733 related to dexamethasone searching for participants."
Share this study with friends
Copy Link
Messenger